Nuntius Therapeutics Analysis: $125K Raised
What is Nuntius Therapeutics?
Nuntius Therapeutics develops transformative mRNA therapies using proprietary delivery technology to target life-threatening diseases like cancer and neurodegenerative disorders.
Employees
2
Founded
2021
Business Model
Business-to-business model; revenue from partnerships and funding rounds.
Product Features & Capabilities
- Genetic medicines, mRNA therapies, programmable nanocarriers, machine learning for carrier selection, superior protein expression mRNA, therapies targeting cancer, lung diseases, neurodegenerative diseases.
How much Nuntius Therapeutics raised
1 - $125,000
March 22, 2021Lead Investor: Asymmetry Ventures, Backed VC, FoundersX Ventures, Uncommon Denominator
Who are the founders of Nuntius Therapeutics
BN
Benita Nagel
Co-founder & CEO
AK
Albert Kwok, PhD
Co-founder & CSO
Market Focus
Nuntius Therapeutics primarily focuses on the biotechnology industry, specifically in the development of mRNA therapies for life-threatening diseases using advanced delivery technologies and nucleic acid engineering.
Investors
- Asymmetry Ventures
- Backed VC
- FoundersX Ventures
- Uncommon Denominator
- Y Combinator
- Eight Capital
- Savantus Ventures
Competitors Overview
Nuntius Therapeutics operates in the mRNA therapy market, focusing on transformative therapies for life-threatening diseases using proprietary delivery technology. Its main competitors include:
- Moderna:
- Overview: A leader in mRNA technology, known for its COVID-19 vaccine and a robu
See something that needs updating? Suggest edits to this profile.